These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30388034)

  • 21. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
    Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
    Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tardive dyskinesia following discontinuation of neuroleptic therapy in 87-year-old patient].
    Lecomte F; Lobbe M; Kohler S; Ketz F; Breining A; Pautas É
    Soins Gerontol; 2019; 24(140):41-42. PubMed ID: 31806178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Withdrawal-Emergent Dyskinesia After Acute Discontinuation of Risperidone in a Child With Autism Spectrum Disorder.
    Kumar M; Mattison R; Baweja R
    J Clin Psychopharmacol; 2018 Dec; 38(6):640-642. PubMed ID: 30285999
    [No Abstract]   [Full Text] [Related]  

  • 24. Tardive dyskinesia with schizophrenic relapse.
    Jawed SH; Singh I
    J Ment Defic Res; 1989 Aug; 33 ( Pt 4)():331-4. PubMed ID: 2570160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive syndromes.
    Savitt D; Jankovic J
    J Neurol Sci; 2018 Jun; 389():35-42. PubMed ID: 29506749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing Treatments for Tardive Dyskinesia.
    Citrome LL
    J Clin Psychiatry; 2017; 78(9):e1429. PubMed ID: 29345877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
    Lanning RK; Zai CC; Müller DJ
    Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate.
    Omer HM; Thompson AD
    Aust N Z J Psychiatry; 2018 May; 52(5):496-497. PubMed ID: 29338294
    [No Abstract]   [Full Text] [Related]  

  • 29. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
    Correll CU; Kane JM; Citrome LL
    J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia: motor system impairments, cognition and everyday functioning.
    Strassnig M; Rosenfeld A; Harvey PD
    CNS Spectr; 2018 Dec; 23(6):370-377. PubMed ID: 28877766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis.
    Park SY; Cervesi C; Galling B; Molteni S; Walyzada F; Ameis SH; Gerhard T; Olfson M; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2016 Jun; 55(6):456-468.e4. PubMed ID: 27238064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valbenazine (Ingrezza) for tardive dyskinesia.
    Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical management of tardive dyskinesia: Five steps to success.
    Citrome L
    J Neurol Sci; 2017 Dec; 383():199-204. PubMed ID: 29246613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia and the mentally handicapped.
    Bicknell DJ; Blowers AJ
    Br J Psychiatry; 1980 Mar; 136():315-6. PubMed ID: 6104521
    [No Abstract]   [Full Text] [Related]  

  • 36. Postural stability, tardive dyskinesia and developmental disability.
    Ko YG; Van Emmerik RE; Sprague RL; Newell KM
    J Intellect Disabil Res; 1992 Aug; 36 ( Pt 4)():309-23. PubMed ID: 1356038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence-Based Strategies for Managing Tardive Dyskinesia.
    McEvoy JP
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of abnormal respiratory movements in schizophrenic, bipolar and mentally handicapped patients with typical tardive dyskinesia.
    Youssef HA; Waddington JL
    Int Clin Psychopharmacol; 1989 Jan; 4(1):55-9. PubMed ID: 2574204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.
    Vijayakumar D; Jankovic J
    Drugs; 2016 May; 76(7):779-87. PubMed ID: 27091214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.